118 related articles for article (PubMed ID: 37861038)
1. Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor:
Beeraka NM; Zhang J; Zhao D; Liu J; A U C; Vikram Pr H; Shivaprakash P; Bannimath N; Manogaran P; Sinelnikov MY; Bannimath G; Fan R
Curr Pharm Des; 2023; 29(30):2408-2425. PubMed ID: 37861038
[TBL] [Abstract][Full Text] [Related]
2. Screening fructosamine-3-kinase (FN3K) inhibitors, a deglycating enzyme of oncogenic Nrf2: Human FN3K homology modelling, docking and molecular dynamics simulations.
Beeraka NM; Zhang J; Mandal S; Vikram P R H; Liu J; B M N; Zhao D; Vishwanath P; B M G; Fan R
PLoS One; 2023; 18(11):e0283705. PubMed ID: 37910519
[TBL] [Abstract][Full Text] [Related]
3. In vitro exosomal transfer of Nrf2 led to the oxaliplatin resistance in human colorectal cancer LS174T cells.
Mostafazadeh M; Kahroba H; Haiaty S; TazeKand AP; Samadi N; Rahbarghazi R; Nouri M
Cell Biochem Funct; 2022 Jun; 40(4):391-402. PubMed ID: 35474580
[TBL] [Abstract][Full Text] [Related]
4. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.
Xie J; Lai Z; Zheng X; Liao H; Xian Y; Li Q; Wu J; Ip S; Xie Y; Chen J; Su Z; Lin Z; Yang X
Toxicology; 2021 Mar; 451():152680. PubMed ID: 33465425
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
7. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
[TBL] [Abstract][Full Text] [Related]
9. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
Jang CH; Moon N; Oh J; Kim JS
Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
[TBL] [Abstract][Full Text] [Related]
10. The potential impact of trigonelline loaded micelles on Nrf2 suppression to overcome oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Salehi R; Velaei K; Samadi N
Mol Biol Rep; 2020 Aug; 47(8):5817-5829. PubMed ID: 32661875
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways.
Yang Y; Tian Z; Guo R; Ren F
Oxid Med Cell Longev; 2020; 2020():9867595. PubMed ID: 32765809
[TBL] [Abstract][Full Text] [Related]
12. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
13. Curcumin Attenuates Oxaliplatin-Induced Liver Injury and Oxidative Stress by Activating the Nrf2 Pathway.
Lu Y; Wu S; Xiang B; Li L; Lin Y
Drug Des Devel Ther; 2020; 14():73-85. PubMed ID: 32021093
[TBL] [Abstract][Full Text] [Related]
14. Neferine and isoliensinine enhance 'intracellular uptake of cisplatin' and induce 'ROS-mediated apoptosis' in colorectal cancer cells - A comparative study.
Manogaran P; Beeraka NM; Huang CY; Vijaya Padma V
Food Chem Toxicol; 2019 Oct; 132():110652. PubMed ID: 31255669
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?
Wu T; Harder BG; Wong PK; Lang JE; Zhang DD
Mol Carcinog; 2015 Nov; 54(11):1494-502. PubMed ID: 25154499
[TBL] [Abstract][Full Text] [Related]
16. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
17. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
18. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
[TBL] [Abstract][Full Text] [Related]
19. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
